Raloxifene: an agent for breast cancer prevention

References

• American Cancer Society. Cancer Facts & Figures. American Cancer Society, GA, USA, 7–11 (2007).
   Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90 (18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Freedman AN, Graubard BI, Rao SR et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl Cancer Inst.95(7), 526–532 (2003).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Knickebocker RK, Nickelsen T, Genant H. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA282 (7), 637–645 (1999).
   PubMed Web of Science ®Google Scholar
• Cummings SE, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE trial. JAMA281, 2189–2197 (1999).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res.Treat.6, 125–134 (2001).
   Google Scholar
• Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst.96 (23), 1751–1761 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett-Conner E, Mosca L, Collins, P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med.355, 125–137 (2006).
   PubMedGoogle Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295, 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH et aI. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med.33, 1641–1647 (1997).
   Google Scholar
• Clemens J, Bennett D, Black L, Jones C. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci.32, 2869–2875 (1983).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology45, 344–345 (1988).
   PubMed Web of Science ®Google Scholar
• Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst.81, 1879–1886 (1989).
   PubMed Web of Science ®Google Scholar
• Land SR, Wickerham DL, Costantino JP et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295, 2742–2751 (2006).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Land SR, Wickerham DL et al. STAR: changes in patient-reported outcomes after the end of treatment. ASCO Annual Proceedings (2007) (Abstract 1506).
   Google Scholar
• Fabian C. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices-counterpoint. Cancer Epidemiol. Biomarkers Prev.16(11), 2210–2211 (2007).
   PubMedGoogle Scholar
• Jordan VC. The science of selective estrogen receptor modulators; concept to clinical practice. Clin. Cancer Res.12(17), 5010–5013 (2006).
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), e25–e146, 2007.
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med.356(16), 1670–1674 (2007).
   PubMed Web of Science ®Google Scholar
• Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilization of hormone replacement therapy. Breast Cancer Res. Treat.107(3), 427–430 (2007).
   PubMedGoogle Scholar
• Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J. Natl Cancer Inst.99(15), 1152–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J. Natl Cancer Inst.99(17), 1335–1339 (2007).
   PubMed Web of Science ®Google Scholar